Merck (MRK) closed at $96.24 in the latest trading session, marking a -1.72% move from the prior day. This change lagged the S&P 500's daily gain of 0.88%. Elsewhere, the Dow saw an upswing of 1.24%, ...

Shares of Merck & Co. Inc. MRK slid 1.72% to $96.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.